Maxim Group Reiterates Buy Rating on PAVmed with $9.75 Average Price Target

PAVmed (PAVM) received a Buy rating from Maxim Group analyst Anthony Vendetti. Vendetti's report highlights PAVmed's recent earnings release, which reported a quarterly revenue of $6 million and a GAAP net loss of $13.31 billion. The analyst consensus rating for PAVmed is Moderate Buy with an average price target of $9.75. Vendetti's average return on recommended stocks is -26.2% and success rate is 23.84%.

PAVmed Inc. (PAVM), a diversified commercial-stage medical technology company, has received a Buy rating from Maxim Group analyst Anthony Vendetti. The analyst's report highlights PAVmed's recent earnings release, which reported a quarterly revenue of $6 million and a GAAP net loss of $13.31 billion. Vendetti's rating comes with an average price target of $9.75, positioning PAVmed as a moderate buy with a consensus rating of Moderate Buy.

The analyst's report also notes that Vendetti's average return on recommended stocks is -26.2% and his success rate is 23.84%. Despite these figures, the analyst remains optimistic about PAVmed's future prospects, citing the company's recent strategic partnerships, product advancements, and expanding market opportunities.

PAVmed's recent financial performance has been marked by significant investments in its subsidiary Lucid Diagnostics Inc. (LUCD), which specializes in cancer prevention medical diagnostics. Lucid Diagnostics has seen a notable increase in test volumes and revenue, with a record 4,042 EsoGuard tests processed in the fourth quarter of 2024, representing a 45% sequential and 84% annual increase [24].

The company has also secured several strategic partnerships and commercial insurance coverage policies for its innovative products, such as the EsoGuard® Esophageal DNA Test. These developments indicate a growing market acceptance and potential for increased revenue streams in the future.

In summary, while PAVmed's recent earnings report shows a significant net loss, the analyst's Buy rating reflects optimism about the company's long-term potential. The report underscores the importance of strategic investments, product innovation, and market expansion in driving future growth and profitability.

References:
[1] https://ir.pavmed.com/press-releases?l=50
[24] https://ir.pavmed.com/press-releases/l=50